These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 13453515)

  • 1. Clotting of hemophilic blood with purified platelet cofactor I, platelet factor 3 and threone.
    SEEGERS WH; LANDABURU RH; HOLBURN RR; TOCANTINS LM
    Proc Soc Exp Biol Med; 1957 Jul; 95(3):583-5. PubMed ID: 13453515
    [No Abstract]   [Full Text] [Related]  

  • 2. Interaction of convertin with platelets and with platelet-free and hemophilic plasma.
    DE VRIES A; KREJNIS E; SHAFRIR E
    Acta Haematol; 1956 Sep; 16(3):204-13. PubMed ID: 13354260
    [No Abstract]   [Full Text] [Related]  

  • 3. Prothrombin utilization following addition of platelet confactor I concentrates to hemophilic plasma.
    JOHNSON JF; MAMMEN EF; SEEGERS WH
    Thromb Diath Haemorrh; 1959 Sep; 3():588-92. PubMed ID: 14407473
    [No Abstract]   [Full Text] [Related]  

  • 4. Antihemophilic factor (AHF): plasma levels after administration of AHF preparations to hemophilic dogs.
    WAGNER RH; LANGDELL RD; RICHARDSON BA; FARRELL RA; BRINKHOUS KM
    Proc Soc Exp Biol Med; 1957 Oct; 96(1):152-5. PubMed ID: 13485042
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease.
    Bouma BN; Wiegerinck Y; Sixma JJ; Van Mourik JA; Mochtar IA
    Nat New Biol; 1972 Mar; 236(65):104-6. PubMed ID: 4112547
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum accelerator factors and antihemophilic factor (AHF) in early phases of clotting.
    GRAHAM JB; LANGDELL RD; MORRISON FC; BRINKHOUS KM
    Proc Soc Exp Biol Med; 1954 Oct; 87(1):45-8. PubMed ID: 13224672
    [No Abstract]   [Full Text] [Related]  

  • 7. Presence of factor VIII-related antigen in blood platelets of patients with Von Willebrand's disease.
    Bouma BN; Hordijk-Hos JM; DeGraaf S; Sixma JJ; Van Mourik JA
    Nature; 1975 Oct; 257(5526):510-12. PubMed ID: 1080838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of abnormal preoperative hemostatic tests.
    Bowie EJ; Owen CA
    Prog Hemost Thromb; 1980; 5():179-209. PubMed ID: 6775346
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombelastographic observations on the characteristics of hemophilic, thrombocytopenic and heparinized blood.
    DE NICOLA P; MAZZETTI GM
    Blood; 1956 Jan; 11(1):71-80. PubMed ID: 13276486
    [No Abstract]   [Full Text] [Related]  

  • 10. Assay of von Willebrand factor in von Willebrand's disease and hemophilia: use of a macroscopic platelet aggregation test.
    Brinkhous KM; Graham JE; Cooper HA; Allain JP; Wagner RH
    Thromb Res; 1975 Mar; 6(3):267-72. PubMed ID: 1078735
    [No Abstract]   [Full Text] [Related]  

  • 11. THE KAOLIN CLOTTING TIME OF PLATELET-RICH PLASMA: A TEST OF PLATELET FACTOR-3 AVAILABILITY.
    HARDISTY RM; HUTTON RA
    Br J Haematol; 1965 May; 11():258-68. PubMed ID: 14282063
    [No Abstract]   [Full Text] [Related]  

  • 12. Bleeding time after aspirin in disorders of intrinsic clotting.
    Kaneshiro MM; Mielke CH; Kasper CK; Rapaport SI
    N Engl J Med; 1969 Nov; 281(19):1039-42. PubMed ID: 5307310
    [No Abstract]   [Full Text] [Related]  

  • 13. Factor VIII-related activities in normal, haemophilic and von Willebrand's disease platelet fractions.
    Meucci P; Peake IR; Bloom AL
    Thromb Haemost; 1978 Oct; 40(2):288-301. PubMed ID: 310585
    [No Abstract]   [Full Text] [Related]  

  • 14. Factor VIII/von Willebrand factor.
    Zimmerman TS; Ruggeri ZM; Fulcher CA
    Prog Hematol; 1983; 13():279-309. PubMed ID: 6422506
    [No Abstract]   [Full Text] [Related]  

  • 15. The mode of action and aetiology of antihaemophilic globulin inhibitors.
    BIGGS R; BIDWELL E; MACFARLANE RG
    Sang; 1959; 30():340-51. PubMed ID: 13800639
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on factor VIII activation potential in hemophilia A-plasma and its significance for the comprehension of hemophilia.
    Mingers AM
    Eur J Pediatr; 1976 Oct; 123(3):187-98. PubMed ID: 1086208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the Factor VIII/von Willebrand factor antigen on human platelets.
    Coller BS; Hirschman RJ; Gralnick HR
    Thromb Res; 1975 Jun; 6(6):469-80. PubMed ID: 1098217
    [No Abstract]   [Full Text] [Related]  

  • 18. A method for the study of antihaemophilic globulin inhibitors with reference to six cases.
    BIGGS R; BIDWELL E
    Br J Haematol; 1959 Oct; 5():379-95. PubMed ID: 13800640
    [No Abstract]   [Full Text] [Related]  

  • 19. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.
    Brinkhous KM; Sandberg H; Garris JB; Mattsson C; Palm M; Griggs T; Read MS
    Proc Natl Acad Sci U S A; 1985 Dec; 82(24):8752-6. PubMed ID: 3936044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Factor VIII (anti-hemophilic A factor). Biology, physiology, pathology and genetics].
    Meyer D; Dray L; Allain JP; Larrieu MJ
    Pathol Biol (Paris); 1972; 20(11):607-23. PubMed ID: 4558579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.